atopic dermatitis

Micreos initiates clinical trial to evaluate endolysin-drug in atopic dermatitis
Micreos initiates clinical trial to evaluate endolysin-drug in atopic dermatitis
Pharmaceutical Business Review
Micreos Human Health
atopic dermatitis
clinical trials
XZ.700
Flag link:
AbbVie's Rinvoq Hits the Mark in Pivotal Phase III Dermatitis Trial
AbbVie's Rinvoq Hits the Mark in Pivotal Phase III Dermatitis Trial
BioSpace
AbbVie
Rinvoq
atopic dermatitis
clinical trials
Flag link:
Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug
Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug
Yahoo/SmarterAnalyst
Sanofi
Regeneron
China
Dupixent
atopic dermatitis
Flag link:
AAD 2020 – Leo’s eczema wildcard proves tame
AAD 2020 – Leo’s eczema wildcard proves tame
EP Vantage
LEO Pharma
Sanofi
Regeneron
eczema
atopic dermatitis
AAD
tralokinumab
Flag link:
Pfizer's JAK abrocitinib comes through in teen eczema test
Pfizer's JAK abrocitinib comes through in teen eczema test
Fierce Biotech
Pfizer
abrocitinib
eczema
atopic dermatitis
clinical trials
Flag link:
Sanofi and Regeneron's Dupixent Scores Another Approval for Dermatitis, This Time in Kids
Sanofi and Regeneron's Dupixent Scores Another Approval for Dermatitis, This Time in Kids
BioSpace
Sanofi
Regeneron
Dupixent
atopic dermatitis
pediatric
Flag link:
Aslan's Dupixent rival test put on hold amid COVID-19, but delays shouldn't hit readout
Aslan's Dupixent rival test put on hold amid COVID-19, but delays shouldn't hit readout
Fierce Biotech
Aslan Pharma
ASLAN004
Regeneron
Sanofi
Dupixent
atopic dermatitis
Flag link:
Sanofi and Regeneron's Dupixent shows more encouraging results
Sanofi and Regeneron's Dupixent shows more encouraging results
Reuters
Sanofi
Dupixent
atopic dermatitis
clinical trials
Flag link:
Pfizer Wins New Pediatric Approval for Atopic Dermatitis Ointment Eucrisa
Pfizer Wins New Pediatric Approval for Atopic Dermatitis Ointment Eucrisa
BioSpace
Pfizer
FDA
Eucrisa
pediatric
atopic dermatitis
Flag link:
Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day
Pfizer Posts Positive Results in Two Phase III Studies, Postpones Investor Day
BioSpace
Pfizer
clinical trials
atopic dermatitis
pneumococcal disease
20VPnC
vaccines
abrocitinib
Flag link:
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Incyte hits endpoint in 2nd pivotal atopic dermatitis trial
Fierce Biotech
Incyte
ruxolitinib
clinical trials
atopic dermatitis
Flag link:
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Eli Lilly and Incyte Record Another Positive Clinical Trial for Olumiant Works in Eczema
Motley Fool
Eli Lilly
Incyte
olumiant
eczema
clinical trials
atopic dermatitis
Flag link:
Incyte's skin disease drug meets main goal in late-stage study
Incyte's skin disease drug meets main goal in late-stage study
Yahoo/Reuters
Incyte
clinical trials
atopic dermatitis
ruxolitinib
Flag link:
Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczema
Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczema
Pharmaforum
Sanofi
Dupixent
NHS
Wales
Scotland
atopic dermatitis
Flag link:
Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion
Eli Lilly Bags Dermatology Company Dermira for $1.1 Billion
BioSpace
Eli Lilly
Dermira
dermatology
M&A
atopic dermatitis
Flag link:
Leo's Dupixent rival hits all endpoints in pivotal program
Leo's Dupixent rival hits all endpoints in pivotal program
Fierce Biotech
LEO Pharma
atopic dermatitis
tralokinumab
Sanofi
Regeneron
Dupixent
Flag link:
Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis
Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis
Pharmaceutical Business Review
Demira
atopic dermatitis
FDA
fast track
Flag link:
Dupixent's already a blockbuster, but there's much more to come: Sanofi exec
Dupixent's already a blockbuster, but there's much more to come: Sanofi exec
Fierce Pharma
Sanofi
Dupixent
atopic dermatitis
Flag link:
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Fierce Biotech
MorphoSys
Galapagos
Novartis
MOR106
atopic dermatitis
Dupixent
Sanofi
Flag link:
RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193
Pharmaceutical Business Review
RAPT Therapeutics
RPT193
allergies
atopic dermatitis
clinical trials
Flag link:

Pages